DK1409012T3 - Fremgangsmåder til fremkaldelse af et cytotoksisk immunrespons og derved anvendelige rekombinante abe-adenovirussammensætninger - Google Patents
Fremgangsmåder til fremkaldelse af et cytotoksisk immunrespons og derved anvendelige rekombinante abe-adenovirussammensætningerInfo
- Publication number
- DK1409012T3 DK1409012T3 DK02780874T DK02780874T DK1409012T3 DK 1409012 T3 DK1409012 T3 DK 1409012T3 DK 02780874 T DK02780874 T DK 02780874T DK 02780874 T DK02780874 T DK 02780874T DK 1409012 T3 DK1409012 T3 DK 1409012T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- eliciting
- immune response
- cytotoxic immune
- monkey adenovirus
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 241000282693 Cercopithecidae Species 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 title 1
- 230000001939 inductive effect Effects 0.000 abstract 2
- 241000990167 unclassified Simian adenoviruses Species 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 102000003996 Interferon-beta Human genes 0.000 abstract 1
- 108090000467 Interferon-beta Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960001388 interferon-beta Drugs 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30013101P | 2001-06-22 | 2001-06-22 | |
| US30484301P | 2001-07-12 | 2001-07-12 | |
| PCT/US2002/015239 WO2003000283A1 (en) | 2001-06-22 | 2002-05-13 | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1409012T3 true DK1409012T3 (da) | 2009-05-18 |
Family
ID=26971607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02780874T DK1409012T3 (da) | 2001-06-22 | 2002-05-13 | Fremgangsmåder til fremkaldelse af et cytotoksisk immunrespons og derved anvendelige rekombinante abe-adenovirussammensætninger |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040241181A1 (hu) |
| EP (1) | EP1409012B1 (hu) |
| JP (1) | JP2005523233A (hu) |
| KR (1) | KR20040043129A (hu) |
| CN (1) | CN1518457A (hu) |
| AT (1) | ATE422365T1 (hu) |
| AU (1) | AU2002308713B2 (hu) |
| BR (1) | BR0210586A (hu) |
| CA (1) | CA2451864C (hu) |
| CY (1) | CY1109059T1 (hu) |
| CZ (1) | CZ304169B6 (hu) |
| DE (1) | DE60231123D1 (hu) |
| DK (1) | DK1409012T3 (hu) |
| ES (1) | ES2322043T3 (hu) |
| HK (1) | HK1061511A1 (hu) |
| HU (1) | HU228327B1 (hu) |
| IL (2) | IL159454A0 (hu) |
| MX (1) | MXPA04000024A (hu) |
| NO (1) | NO333252B1 (hu) |
| NZ (1) | NZ530245A (hu) |
| PL (1) | PL216200B1 (hu) |
| PT (1) | PT1409012E (hu) |
| SG (1) | SG153649A1 (hu) |
| SI (1) | SI1409012T1 (hu) |
| WO (1) | WO2003000283A1 (hu) |
| ZA (1) | ZA200309360B (hu) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| CA2466431C (en) * | 2001-11-21 | 2014-08-05 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| US7491508B2 (en) * | 2003-06-20 | 2009-02-17 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| LT2163260T (lt) | 2004-01-23 | 2017-06-26 | Msd Italia S.R.L. | Šimpanzės adenoviruso vakcinos nešikliai |
| AU2005293568B2 (en) | 2004-10-13 | 2010-10-28 | Beth Israel Deaconess Medical Center Inc. | Improved adenoviral vectors and uses thereof |
| EP1880012B1 (en) * | 2005-05-12 | 2015-07-08 | Glaxo Group Limited | Vaccine composition |
| SG173377A1 (en) | 2006-07-18 | 2011-08-29 | Glaxosmithkline Biolog Sa | Vaccines for malaria |
| MX362698B (es) | 2007-03-02 | 2019-02-01 | Glaxosmithkline Biologicals Sa | Metodo novedoso y composiciones. |
| AU2008226974B2 (en) * | 2007-03-09 | 2013-08-15 | Merck Sharp & Dohme Llc | Papillomavirus vaccine compositions |
| KR101761683B1 (ko) * | 2007-11-28 | 2017-07-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용 |
| WO2010085984A1 (en) * | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2011057254A2 (en) * | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
| WO2011133870A2 (en) * | 2010-04-22 | 2011-10-27 | Andrea Amalfitano | Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap) |
| CN102060915A (zh) * | 2010-10-29 | 2011-05-18 | 广州呼吸疾病研究所 | 人3型腺病毒六邻体的可修饰位点及其应用 |
| KR20200008014A (ko) * | 2011-03-21 | 2020-01-22 | 알티뮨 인크. | 급속 및 지속적 면역학적제제-치료제 |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| CN103937835A (zh) * | 2013-08-19 | 2014-07-23 | 中国科学院上海巴斯德研究所 | 一种基于腺病毒AdC68的表达载体及其构建方法 |
| CN103468743B (zh) * | 2013-08-19 | 2015-07-29 | 中国科学院上海巴斯德研究所 | 一种狂犬病疫苗及其制备方法 |
| BR112016008806A2 (pt) | 2013-11-01 | 2017-10-03 | Pfizer | Vetores para expressão de antígenos associados à próstata |
| NZ726112A (en) * | 2014-05-19 | 2021-07-30 | Valo Therapeutics Oy | Coated adenoviruses for immunotherapy |
| EP3154576A1 (en) | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| EP3307313A1 (en) | 2015-06-12 | 2018-04-18 | GlaxoSmithKline Biologicals SA | Adenovirus polynucleotides and polypeptides |
| US11498956B2 (en) | 2016-08-23 | 2022-11-15 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain(CD74) |
| US11466292B2 (en) | 2016-09-29 | 2022-10-11 | Glaxosmithkline Biologicals Sa | Compositions and methods of treatment |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| MX2019006722A (es) | 2016-12-09 | 2019-08-22 | Glaxosmithkline Biologicals Sa | Construcciones de adenovirus de chimpance con antigenos de lyssavirus. |
| GB201701239D0 (en) * | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
| WO2019016756A1 (en) | 2017-07-21 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES |
| CN111295391B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| US11459583B2 (en) | 2017-10-31 | 2022-10-04 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| JP7438943B2 (ja) | 2017-10-31 | 2024-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルス及びその用途 |
| MA50502A (fr) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention Bv | Adénovirus et utilisations associées |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| BR112020012361A2 (pt) | 2017-12-20 | 2020-11-24 | Glaxosmithkline Biologicals S.A. | constructos de antígeno do vírus epstein-barr |
| EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
| EP3587581A1 (en) | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
| CA3132601A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
| AU2021309007A1 (en) | 2020-07-13 | 2023-02-16 | Transgene | Treatment of immune depression |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
| US5698202A (en) * | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| AU6261696A (en) * | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| WO2000011140A1 (en) * | 1998-08-20 | 2000-03-02 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
-
2002
- 2002-05-13 EP EP02780874A patent/EP1409012B1/en not_active Expired - Lifetime
- 2002-05-13 IL IL15945402A patent/IL159454A0/xx unknown
- 2002-05-13 HU HU0400297A patent/HU228327B1/hu not_active IP Right Cessation
- 2002-05-13 MX MXPA04000024A patent/MXPA04000024A/es active IP Right Grant
- 2002-05-13 DK DK02780874T patent/DK1409012T3/da active
- 2002-05-13 CA CA2451864A patent/CA2451864C/en not_active Expired - Fee Related
- 2002-05-13 PT PT02780874T patent/PT1409012E/pt unknown
- 2002-05-13 CN CNA028124383A patent/CN1518457A/zh active Pending
- 2002-05-13 KR KR10-2003-7016662A patent/KR20040043129A/ko not_active Application Discontinuation
- 2002-05-13 WO PCT/US2002/015239 patent/WO2003000283A1/en active Search and Examination
- 2002-05-13 AU AU2002308713A patent/AU2002308713B2/en not_active Ceased
- 2002-05-13 AT AT02780874T patent/ATE422365T1/de active
- 2002-05-13 US US10/480,793 patent/US20040241181A1/en not_active Abandoned
- 2002-05-13 NZ NZ530245A patent/NZ530245A/en not_active IP Right Cessation
- 2002-05-13 SI SI200230817T patent/SI1409012T1/sl unknown
- 2002-05-13 JP JP2003506927A patent/JP2005523233A/ja active Pending
- 2002-05-13 BR BR0210586-1A patent/BR0210586A/pt not_active Application Discontinuation
- 2002-05-13 PL PL372294A patent/PL216200B1/pl unknown
- 2002-05-13 ES ES02780874T patent/ES2322043T3/es not_active Expired - Lifetime
- 2002-05-13 CZ CZ20033438A patent/CZ304169B6/cs not_active IP Right Cessation
- 2002-05-13 DE DE60231123T patent/DE60231123D1/de not_active Expired - Lifetime
- 2002-05-13 SG SG200508260-7A patent/SG153649A1/en unknown
-
2003
- 2003-12-02 ZA ZA2003/09360A patent/ZA200309360B/en unknown
- 2003-12-18 IL IL159454A patent/IL159454A/en not_active IP Right Cessation
- 2003-12-19 NO NO20035740A patent/NO333252B1/no not_active IP Right Cessation
-
2004
- 2004-06-14 HK HK04104281.6A patent/HK1061511A1/xx not_active IP Right Cessation
-
2009
- 2009-05-11 CY CY20091100506T patent/CY1109059T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1409012T3 (da) | Fremgangsmåder til fremkaldelse af et cytotoksisk immunrespons og derved anvendelige rekombinante abe-adenovirussammensætninger | |
| MX2022010008A (es) | Composiciones inmunogenicas de coronavirus y usos de las mismas. | |
| HUP0303720A2 (hu) | Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény | |
| NO20061857L (no) | C-klasse oligonukleotid-analoger med okt immunstimulerende potens | |
| MY129263A (en) | Vaccine composition | |
| BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
| DK1401458T3 (da) | Sammensætning bestående af PHY906 og kemoterapeutiske midler | |
| DE60330708D1 (de) | Impfstoff gegen das west-nile-virus | |
| DK1765337T3 (da) | Kombination af tenofovir, ritonavir og TMC114 | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| YU174491A (sh) | Vakcine | |
| DK1429800T3 (da) | Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose | |
| ATE420658T1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
| BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
| WO2005027844A3 (en) | Dna vaccine compositions and methods of use | |
| WO2005120540A3 (en) | Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction | |
| IT1277926B1 (it) | Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire | |
| EP1370697A4 (en) | PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE | |
| AR027738A1 (es) | Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas | |
| DK1448223T3 (da) | Thymosin-forögelse af genetisk immunisering | |
| CY1108543T1 (el) | Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv |